HAC Biomed GmbH

HAC Biomed pioneered the evaluation of a new concept in in vivo tissue engineering, using autologous primary human hepatocytes isolated from diseased livers (explanted during orthotopic liver transplantation) to produce a neo-hybrid liver. The theory is to thus reduce immunogenicity, induce immunoregulation, and consequently minimize the need for extensive immunosuppression and eventually induce operational tolerance.

“Dr. Stange was responsible as an interim manager for building and running a certified clean room laboratory for the hepautocell individual therapy and has accompanied the commercialization and successful reimbursement strategy as a new examination and treatment method”


  • 2006: Company founded
  • 2008-2009: Served as interim COO

Founded: 2006


Silversky GmbH

Brunnenstrasse 23 40223 Düsseldorf

E-Mail: info@silversky-lifesciences.com

Legal disclosure | Datenschutz


I agree that my information from the contact form will be collected and processed to answer my request and stored in case of follow-up questions. We will not share this information without your consent. Note: You can revoke your consent at any time for the future by sending an e-mail to Privacy Policy. For detailed information on how to handle user information, please see our Privacy Policy.